Sorrento nabs key FDA designation for nonopiate drug to treat bone pain in dogs

A compound called resiniferatoxin (RTX), which is derived from a cactuslike plant commonly found in Morocco, has long been pursued as a potential way to treat pain without dangerous opiates. RTX, in fact, is now in a Phase I/II study at the National Institutes of Health to treat intractable pain in people with end-stage cancer. But early trials in pet dogs have shown the toxin to be effective in relieving pain from canine bone cancer and osteoarthritis, too, and now ARK Animal Health, a subsidiary of Sorrento Therapeutics ($SRNE), has received encouragement from the FDA to pursue the compound for veterinary use. The agency granted the company Minor Use/Minor Species (MUMS) designation for its version of RTX, called ARK-001, which it is developing to treat pain in dogs with osteosarcoma. The designation will give ARK 7 years of market exclusivity if the drug is approved. Release

Suggested Articles

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to…

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint…

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--…